ACE and COVID-19: Based on the experimental data on the increased expression of ACE2 in patients with diabetes [11] and hypertension [65] while on ACE inhibitors (ACE-I) or angiotensin II type-I receptor blockers (ARBs) treatment, some authors [11,65,66,67] hypothesized that their use might increase the risk of SAR-COV-2 infection and develop a severe form of COVID-19, through the upregulation of ACE2 expression.